about
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsHigh-content molecular profiling of T-cell therapy in oncologyTargeting the TAM Receptors in LeukemiaNew Therapeutic Strategies in Acute Lymphocytic Leukemia.Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Peptide-guided targeting of GPR55 for anti-cancer therapy.Targeting Human β-Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment.Primary peritoneal carcinoma metastasizing to breast: a single case report and literature review from clinic to biology.Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful.A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?Cancer Immunotherapy: Whence and Whither.The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma.New targeted therapies for malignant lymphoma based on molecular heterogeneity.NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies.Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.Novel treatment concepts in Hodgkin lymphoma.The landscape of new drugs in lymphomaTreatment of Young Adults with Acute Lymphoblastic Leukemia.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Continuing challenges and current issues in acute lymphoblastic leukemia.Pembrolizumab (Keytruda)Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.Antigen-directed therapies: an effective tool in acute myeloid leukemia?Clinical applications of genome studies.The role of novel immunotherapies in non-Hodgkin lymphoma.Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.Antibody darts on target for acute myelogenous leukemia.Clinical trials of CAR-T cells in ChinaTumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.The rocky road to personalized medicine in acute myeloid leukaemia.
P2860
Q26745842-95E5C8B9-29CF-447B-8047-C45D6FFA8BDFQ28066792-8317A018-2413-4DF6-9493-49C625B4DB45Q28078654-B246A333-16A9-415A-A1C5-9A558A27F5CEQ30252776-6BAE09A1-ED84-4BBB-A551-A444424B8B0AQ33561644-D3D7638D-EA43-4AFB-8B39-DB12E120B3EAQ33622342-7E40F6E2-BD6B-480D-BDD2-AAE5DACD1BAAQ33632104-B5EB1733-74BB-463D-BC28-A55814526888Q33638083-1A3079E7-8FA2-41AF-8CCB-5EA38B064E94Q33698398-EE4BCD4C-95E7-47B2-A4E8-257EB71F5AB4Q33823270-F3EDBF5A-6233-4A88-B460-73411F9A25B7Q36234465-41EE4CCF-1FE4-4FEB-B9DC-14CBAEC753A6Q37138590-4931B3B1-6895-4C12-A1CD-F1BFED79BA4DQ37349409-9806D624-3E8D-4ADC-BFDD-0601C03B8B8DQ37589543-9FC21A11-C346-4D08-9CB2-2E9756348870Q38674589-93D25382-3B9C-4A15-B26A-A110ACF6E05AQ38700209-267E4031-40AD-410E-A00A-8C4BCA4A8F14Q38737924-3018D8BE-29BC-43E2-B1E5-9565BC366532Q38745141-16B8DAE7-8924-428A-B060-C11F80C9B137Q38787141-858C76C5-B07C-4809-A940-B56CE8B09213Q38788557-31067D15-E45E-481A-BB22-798D20850AA4Q38839878-800C904F-17EB-45C4-BD12-49E454348473Q38878902-BEA7D6D1-802A-4F78-AD20-9571C0ECB41CQ38889427-D6A53734-59C9-4D03-ADD5-94362DB86834Q39013616-56574849-D240-4BF6-81D5-BEA9B80B13B3Q39043082-EEB62B88-B1EF-4CC2-96F2-77119ED32441Q39061630-ABF5D8F3-CBC8-4A11-8884-5D17DF011BECQ39206217-CECCD382-87A5-4B45-B08C-69AEC879DAD0Q39280002-E8EC29AD-5B26-4075-BC06-416D41A5EC09Q39366299-56BF36DC-9347-4880-B9A1-903B4D37FC39Q39615516-051B9687-1AC0-4C82-B377-34ABB5BC959BQ40396529-EE8960EA-E6AD-4C50-8FF8-13B75171C7A2Q40590788-854EA09B-F5F8-4953-B0BB-64894501E64DQ41692369-383C33F5-8856-40D1-961E-B9701882F4ADQ41695080-696BFFE9-1929-4FB1-8664-9AC367A57440Q41843869-D5F2B9F5-DCBF-4C53-AD29-3C1DD5DB9D8EQ42318343-F87DA9E9-FA1C-428A-AE3D-EA76C5307AEEQ42654456-17664135-B3AE-4045-8A36-77A6036E9F59Q47218634-DAF45089-E28A-48C5-BBA1-E59D87C1B8D8Q47381391-2F3D96CC-DD3E-4AF6-908C-5D2941768B5FQ47561008-87315CC3-68E5-492F-865E-78C0AE3D0F69
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Novel immunotherapies in lymphoid malignancies
@ast
Novel immunotherapies in lymphoid malignancies
@en
Novel immunotherapies in lymphoid malignancies
@nl
type
label
Novel immunotherapies in lymphoid malignancies
@ast
Novel immunotherapies in lymphoid malignancies
@en
Novel immunotherapies in lymphoid malignancies
@nl
prefLabel
Novel immunotherapies in lymphoid malignancies
@ast
Novel immunotherapies in lymphoid malignancies
@en
Novel immunotherapies in lymphoid malignancies
@nl
P2093
P2860
P3181
P1476
Novel immunotherapies in lymphoid malignancies
@en
P2093
Anas Younes
Eri Matsuki
Renier J Brentjens
P2860
P3181
P356
10.1038/NRCLINONC.2015.187
P407
P577
2015-11-03T00:00:00Z